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In his letter to the editor, De Broe et al.1 states that
‘lanthanum appears to have an innocent localization, being
confined to the hepatic endosomal/lysosomal compartment
during passage through the liver into bile.’ For the well-
being of our patients, we certainly hope that this is correct.
De Broe et al. also states that in a 78-week study,
lanthanum accumulation in rats reaches a steady state.
This study was carried out in normal rats, not uremic
animals. Whereas we saw this trend in normal rats as well,
in uremic rats, we saw progressive accumulation of
lanthanum in the liver that did not reach a steady state
over the course of our 110-day study. We are not concerned
with what happens in normal rats as normal individuals
will not be taking lanthanum carbonate. The greater
accumulation of lanthanum in liver of uremic rats is likely
owing to the increased gastrointestinal absorption of
lanthanum seen in uremia which has been reported by
several laboratories, including De Broe’s group. More work
needs to be carried out in order to understand the
mechanism(s) behind this increased gastrointestinal ab-
sorption. In reference to the table included in De Broe’s
letter, we are glad to see that liver enzymes in patients
taking lanthanum carbonate for up to 2 years seem
unaffected. Although liver enzymes are good indicators
of hepatic integrity, cases of cirrhosis have been seen in the
presence of normal liver enzymes, and liver biopsy is the
gold standard in assessing the integrity of hepatic tissue. At
no point do we suggest that lanthanum carbonate produces
liver toxicity, but we feel that the progressive accumulation
of lanthanum seen in uremic rats dictates close monitoring
of those patients taking lanthanum carbonate. Our
concern is for our patients.
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To the Editor: Hill et al.1 describe the role of loss of
autoregulation with afferent arteriolar dilatation as a major
mechanism for progression of hypertensive nephrosclerosis
in man. Failure of autoregulation, however, can also occur
with excessive vasoconstriction with eventual anatomical
narrowing of the pre-glomerular vasculature leading to
glomerular ischemia, wrinkling collapse, and obsolescent
glomeruli.2 Glomerular ischemia leading to glomerular
obsolescence is unlikely to lead directly to increasing
proteinuria, whereas focal glomerulosclerosis secondary to
hypertrophy of remaining intact nephrons is likely to
produce increasing proteinuria. Most renal biopsies, which
result in a diagnosis of hypertensive nephrosclerosis, are
performed in patients with stage 2–4 chronic renal failure and
significant proteinuria. In this study, mean proteinuria was
4 g/24 h and the median value was 3 g/24 h. In contrast, in
the African American Studies in Kidney Disease study
mean glomerular filtration rate was 45 ml/min, mean pro-
teinuria was 0.5 g/24 h, median proteinuria was 80 mg/24 h,
and two-thirds of the patients had proteinuria less than
300 mg/24 h.3 Subjects with proteinuria less than 300 mg/24 h
had a significant increase in glomerular filtration rate in
response to Amlodipine, which reduces pre-glomerular vas-
cular resistance; patients with proteinuria above 300 mg/dl
had no increase in glomerular filtration rate.4 These
observations support the concept that pre-renal vasoconstric-
tion is the earlier lesion in hypertensive nephrosclerosis. In a
recent biopsy study of Caucasian patients in Norway,
predominant pre-glomerular arterial changes with glomeru-
lar capillary collapse were also seen.
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Dr Luke presents briefly here and more extensively in his
paper1 the hypothesis that inappropriate vasoconstriction
to some glomeruli (in a sense a form of loss of
autoregulation) leads to ischemic glomerulosclerosis and
that the remaining nephrons undergo compensatory
hypertrophy with proteinuria and focal segmental glomer-
ulosclerosis. However, in our normal aging kidneys,2
hypertrophic/focal segmental glomerulosclerosis-type glo-
meruli were much more common than ischemic ones, the
reverse of what Dr Luke’s hypothesis might predict. In this
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